Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors

摘要: In an attempt to develop better therapeutic approaches for metastatic renal cell carcinoma (RCC), the combination of antiangiogenic drug sunitinib with gemcitabine was studied. Using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), we have previously determined that a dosage 20 mg/kg per day increased kidney tumor perfusion and decreased vascular permeability in preclinical murine RCC model. This causing regularization vessels selected improve delivery tumor. DCE-MRI used monitor vasculature tumors schedule gemcitabine. We established effective nontoxic combined consisting pretreatment 3 days followed by four treatments at given apart while continuing daily treatment. treatment caused significant growth inhibition resulting small residual nodules exhibiting giant cells degenerative changes, which were observed both spontaneous lung metastases, suggesting systemic antitumor response. The therapy increase mouse survival. monitoring changes induced sunitinib, gemcitabine, showed tumors. These findings, confirmed histologically thinning blood vessels, suggest exert effects addition cytotoxic activity. studies show can be select dose drugs chemotherapy its efficacy.